The 10-second takeaway
For the quarter ended March 31 (Q1), Hospira met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded slightly. Non-GAAP earnings per share grew. GAAP earnings per share dropped to a loss.
Margins contracted across the board.
Hospira booked revenue of $988.3 million. The nine analysts polled by S&P Capital IQ expected revenue of $982.9 million on the same basis. GAAP reported sales were 8.5% lower than the prior-year quarter's $965.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.52. The 13 earnings estimates compiled by S&P Capital IQ predicted $0.44 per share. Non-GAAP EPS of $0.52 for Q1 were 11% higher than the prior-year quarter's $0.47 per share. GAAP EPS were -$0.46 for Q1 compared to $0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 17.0%, much worse than the prior-year quarter. Operating margin was -12.4%, much worse than the prior-year quarter. Net margin was -8.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $1.03 billion. On the bottom line, the average EPS estimate is $0.51.
Next year's average estimate for revenue is $4.11 billion. The average EPS estimate is $2.03.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 132 members out of 160 rating the stock outperform, and 28 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Hospira a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hospira is hold, with an average price target of $30.54.
- Add Hospira to My Watchlist.